A citation-based method for searching scientific literature

Yonina R Murciano-Goroff, Anne Marie McCarthy, Mirar N Bristol, Peter Groeneveld, Susan M Domchek, U Nkiru Motanya, Katrina Armstrong. Breast Cancer Res Treat 2018
Times Cited: 4







List of co-cited articles
19 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, Steven Shak, Gabriel N Hortobagyi, Robert B Livingston, I-Tien Yeh, Peter Ravdin, Roberto Bugarini, Frederick L Baehner, Nancy E Davidson,[...]. Lancet Oncol 2010
897
75

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer, Elizabeth C Dees, Matthew P Goetz, John A Olson,[...]. N Engl J Med 2018
715
75

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, Jennifer Tetzlaff, Douglas G Altman. PLoS Med 2009
50

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
R Peto, C Davies, J Godwin, R Gray, H C Pan, M Clarke, D Cutter, S Darby, P McGale, C Taylor,[...]. Lancet 2012
50

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Ulrike Nitz, Oleg Gluz, Matthias Christgen, Ronald E Kates, Michael Clemens, Wolfram Malter, Benno Nuding, Bahriye Aktas, Sherko Kuemmel, Toralf Reimer,[...]. Breast Cancer Res Treat 2017
70
50

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, Bernard Fisher, Soonmyung Paik, Steven Shak, Joseph P Costantino, Drew Watson, Charles E Geyer, D Lawrence Wickerham, Norman Wolmark. J Clin Oncol 2010
362
50

The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.
Richard H de Boer, Caroline Baker, David Speakman, Calvin Y Chao, Carl Yoshizawa, G Bruce Mann. Med J Aust 2013
46
50

Experiences and attitudes toward risk of recurrence testing in women with breast cancer: a systematic review.
Laura E Leggett, Diane L Lorenzetti, Tom Noseworthy, Simran Tiwana, Gail Mackean, Fiona Clement. Breast Cancer Res Treat 2014
11
50

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, Christopher Wale, John Forbes, Elizabeth A Mallon, Janine Salter, Emma Quinn, Anita Dunbier, Michael Baum, Aman Buzdar,[...]. J Clin Oncol 2010
470
50

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
W Eiermann, M Rezai, S Kümmel, T Kühn, M Warm, K Friedrichs, A Schneeweiss, S Markmann, H Eggemann, J Hilfrich,[...]. Ann Oncol 2013
103
50

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, John Norton, Karen Rychlik, Jeffrey Smerage, Joseph Kash, Helen K Chew, Ellen R Gaynor, Daniel F Hayes, Andrew Epstein,[...]. J Clin Oncol 2010
227
50

Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Sofia Torres, Maureen Trudeau, Sonal Gandhi, Ellen Warner, Sunil Verma, Kathleen I Pritchard, Teresa Petrella, Mark Hew-Shue, Calvin Chao, Andrea Eisen. Oncologist 2018
11
50


Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
J Loncaster, A Armstrong, S Howell, G Wilson, R Welch, A Chittalia, W J Valentine, N J Bundred. Eur J Surg Oncol 2017
34
50


Association of 21-gene recurrence score assay and adjuvant chemotherapy use in the medicare population, 2008-2011.
Kevin W Su, Jane Hall, Pamela R Soulos, Maysa M Abu-Khalaf, Suzanne B Evans, Sarah S Mougalian, Charles E Rutter, Amy J Davidoff, Cary P Gross. J Geriatr Oncol 2016
10
50

The Nottingham Prognostic Index in primary breast cancer.
M H Galea, R W Blamey, C E Elston, I O Ellis. Breast Cancer Res Treat 1992
712
50

Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer.
Steven J Katz, Irina Bondarenko, Kevin C Ward, Ann S Hamilton, Monica Morrow, Allison W Kurian, Timothy P Hofer. JAMA Surg 2018
14
50

Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
Allison W Kurian, Yun Li, Ann S Hamilton, Kevin C Ward, Sarah T Hawley, Monica Morrow, M Chandler McLeod, Reshma Jagsi, Steven J Katz. J Clin Oncol 2017
129
50

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
Fabrice Andre, Nofisat Ismaila, N Lynn Henry, Mark R Somerfield, Robert C Bast, William Barlow, Deborah E Collyar, M Elizabeth Hammond, Nicole M Kuderer, Minetta C Liu,[...]. J Clin Oncol 2019
73
25


Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
Allison W Kurian, Irina Bondarenko, Reshma Jagsi, Christopher R Friese, M Chandler McLeod, Sarah T Hawley, Ann S Hamilton, Kevin C Ward, Timothy P Hofer, Steven J Katz. J Natl Cancer Inst 2018
33
25

Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.
Miguel Martín, Milagros González-Rivera, Serafín Morales, Juan de la Haba-Rodriguez, Lucía González-Cortijo, Luis Manso, Joan Albanell, Antonio González-Martín, Sónia González, Angels Arcusa,[...]. Curr Med Res Opin 2015
20
25

Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals.
Purificación Martínez Del Prado, Isabel Alvarez-López, Severina Domínguez-Fernández, Arrate Plazaola, Oliver Ibarrondo, Elena Galve-Calvo, Nerea Ancizar-Lizarraga, María Gutierrez-Toribio, Ainhara Lahuerta-Martínez, Javier Mar. Clinicoecon Outcomes Res 2018
5
25


Real-world economic value of a 21-gene assay in early-stage breast cancer.
Stanley E Waintraub, Donna McNamara, Deena Mary Atieh Graham, Andrew L Pecora, John Min, Tommy Wu, Hyun Gi Noh, Jacqueline Connors, Ruth Pe Benito, Kelly Choi,[...]. Am J Manag Care 2017
4
25

Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
Hideko Yamauchi, Chizuko Nakagawa, Shinji Yamashige, Hiroyuki Takei, Hiroshi Yagata, Atsushi Yoshida, Naoki Hayashi, John Hornberger, Tiffany Yu, Calvin Chao,[...]. BMC Health Serv Res 2014
15
25

Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing.
Lesley Fallowfield, Lucy Matthews, Shirley May, Valerie Jenkins, David Bloomfield. Psychooncology 2018
9
25

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, Gong Tang, Chungyeul Kim, Joffre Baker, Maureen Cronin, Frederick L Baehner, Michael G Walker, Drew Watson, Taesung Park,[...]. N Engl J Med 2004
25

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, Jan Bogaerts, Leen Slaets, Giuseppe Viale, Suzette Delaloge, Jean-Yves Pierga, Etienne Brain, Sylvain Causeret, Mauro DeLorenzi,[...]. N Engl J Med 2016
749
25

PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies.
Robert F Wolff, Karel G M Moons, Richard D Riley, Penny F Whiting, Marie Westwood, Gary S Collins, Johannes B Reitsma, Jos Kleijnen, Sue Mallett. Ann Intern Med 2019
235
25

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.
H A Azim, S Michiels, F Zagouri, S Delaloge, M Filipits, M Namer, P Neven, W F Symmans, A Thompson, F André,[...]. Ann Oncol 2013
98
25

A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.
J A Davidson, I Cromwell, S L Ellard, C Lohrisch, K A Gelmon, T Shenkier, D Villa, H Lim, S Sun, S Taylor,[...]. Eur J Cancer 2013
39
25

Examination of Health System Resources and Costs Associated With Transitioning Cancer Survivors to Primary Care: A Propensity-Score-Matched Cohort Study.
Nicole Mittmann, Hasmik Beglaryan, Ning Liu, Soo Jin Seung, Farah Rahman, Julie Gilbert, Stefanie De Rossi, Craig C Earle, Eva Grunfeld, Victoria Zwicker,[...]. J Oncol Pract 2018
7
25

The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
Roland C Y Leung, Thomas C C Yau, Miranda C M Chan, Sharon W W Chan, Terence W C Chan, Yvonne Y Y Tsang, Ting Ting Wong, Calvin Chao, Carl Yoshizawa, Inda S Soong,[...]. Clin Breast Cancer 2016
14
25

Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, Elena Lopez-Knowles, Kalvinder Sidhu, Anita K Dunbier, J Wayne Cowens, Sean Ferree, James Storhoff, Carl Schaper, Jack Cuzick. J Clin Oncol 2013
371
25


First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Maria Vittoria Dieci, Valentina Guarneri, Tommaso Giarratano, Marta Mion, Giampaolo Tortora, Costanza De Rossi, Stefania Gori, Cristina Oliani, Laura Merlini, Felice Pasini,[...]. Oncologist 2018
7
25

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
N Lynn Henry, Mark R Somerfield, Vandana G Abramson, Kimberly H Allison, Carey K Anders, Diana T Chingos, Arti Hurria, Thomas H Openshaw, Ian E Krop. J Clin Oncol 2016
53
25

Understanding how breast cancer patients use risk information from genomic tests.
Jessica T DeFrank, Lisa A Carey, Noel T Brewer. J Behav Med 2013
13
25

Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis.
Bernardo Amadeo Leone, Carlos Teodoro Vallejo, Alberto Omar Romero, Mario Raúl Machiavelli, Juan Eduardo Pérez, Julieta Leone, José Pablo Leone. Breast Cancer Res Treat 2017
45
25


Limitations of Personalized Medicine and Gene Assays for Breast Cancer.
David Tiberi, Laura Masucci, Daniel Shedid, Isabelle Roy, Toni Vu, Erica Patocskai, André Robidoux, Philip Wong. Cureus 2017
6
25

Patterns and predictors of first and subsequent recurrence in women with early breast cancer.
Y M Geurts, A Witteveen, R Bretveld, P M Poortmans, G S Sonke, L J A Strobbe, S Siesling. Breast Cancer Res Treat 2017
40
25

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Ivana Sestak, Miguel Martín, Peter Dubsky, Ralf Kronenwett, Federico Rojo, Jack Cuzick, Martin Filipits, Amparo Ruiz, William Gradishar, Hatem Soliman,[...]. Breast Cancer Res Treat 2019
28
25

Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.
Malek B Hannouf, Gregory S Zaric, Phillip Blanchette, Christine Brezden-Masley, Mike Paulden, Christopher McCabe, Jacques Raphael, Muriel Brackstone. Pharmacogenomics J 2020
11
25

Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Mike Paulden, Jacob Franek, Ba' Pham, Philippe L Bedard, Maureen Trudeau, Murray Krahn. Value Health 2013
22
25

European inter-institutional impact study of MammaPrint.
P G Cusumano, D Generali, E Ciruelos, L Manso, I Ghanem, E Lifrange, G Jerusalem, J Klaase, F de Snoo, L Stork-Sloots,[...]. Breast 2014
19
25


Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
Patricia R Blank, Martin Filipits, Peter Dubsky, Florian Gutzwiller, Michael P Lux, Jan C Brase, Karsten E Weber, Margaretha Rudas, Richard Greil, Sibylle Loibl,[...]. Pharmacoeconomics 2015
10
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.